X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077
https://www.fiercepharma.com/pharma/novartis-amgen-settle-their-dueling-lawsuits-over-migraine-drug-aimovig
https://www.europeanpharmaceuticalreview.com/news/165242/aimovigdisplays-superiority-over-topiramate-in-migraine-study/
https://www.fiercepharma.com/pharma/abbvie-pressures-biohaven-migraine-prevention-fda-approval-for-cgrp-blockbuster-to-be
https://www.fiercebiotech.com/biotech/migraine-market-better-make-way-for-abbvie-as-oral-preventative-treatment-atogepant-poised
https://www.prnewswire.com/news-releases/amgen-announces-approval-of-aimovig-erenumab-in-japan-for-the-suppression-of-onset-of-migraine-attacks-in-adults-301318079.html
https://www.fiercepharma.com/pharma/novartis-to-hand-over-u-s-aimovig-operations-to-amgen-amid-crowded-migraine-market-slashes
https://www.clinicaltrialsarena.com/news/novartis-migraine-medicine-trial/
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iv-study-showing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention
http://www.pharmafile.com/news/560744/aimovig-reduces-frequency-episodic-migraines-five-year-data-reveals
http://www.pharmafile.com/news/560744/aimovig-reduces-frequency-episodic-migraines-five-year-data-reveals
https://www.fiercepharma.com/marketing/novartis-final-migraine-study-readout-finds-employer-support-matters-shows-productivity
https://www.fiercepharma.com/pharma/novartis-and-amgen-tout-aimovig-s-benefits-real-world-and-long-term-data
http://www.pharmatimes.com/news/new_data_back_long-term_use_of_novartis_aimovig_in_migraine_1338485
http://www.pharmatimes.com/news/new_data_back_long-term_use_of_novartis_aimovig_in_migraine_1338485
https://www.novartis.com/news/media-releases/novartis-announces-data-neurology-reinforcing-real-world-and-long-term-effectiveness-and-safety-aimovig-preventive-treatment-across-full-spectrum-migraine
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077
http://www.pharmatimes.com/news/nice_to_request_aimovig_evidence,_appeal_panel_rules_1324244
http://www.pmlive.com/pharma_news/amgen_exits_neuroscience_r_and_d_to_focus_on_growth_areas_1314963
https://in.reuters.com/article/us-amgen-results/amgen-posts-higher-biosimilar-sales-ends-neuroscience-program-idINKBN1X82GQ
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077
https://www.fiercepharma.com/pharma/cgrp-market-race-heats-up-amgen-s-aimovig-slips-under-50-lilly-s-emgality-rise
http://www.pharmatimes.com/news/aimovig_shows_long-term_efficacy_where_other_treatments_fail_1292940
https://www.fiercepharma.com/marketing/eli-lilly-turns-to-patients-to-market-new-emgality-indication-cluster-headaches
https://www.fiercepharma.com/pharma/lilly-scores-cluster-headache-nod-for-emgality-how-will-it-affect-cgrp-race
https://www.prnewswire.com/news-releases/amgen-to-highlight-extensive-long-term-safety-and-efficacy-data-of-aimovig-erenumab-aooe-across-the-spectrum-of-migraine-at-aan-annual-meeting-300843004.html
https://www.fiercepharma.com/pharma/key-drugs-repatha-aimovig-flail-as-cheap-copies-eat-into-amgen-sales
https://www.reuters.com/article/us-usa-drugpricing-migraine-insight/the-obscure-advisory-committees-at-the-heart-of-the-u-s-drug-pricing-debate-idUSKCN1S51E7?feedType=RSS&feedName=healthNews
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077
https://www.fiercepharma.com/marketing/even-under-new-competition-botox-can-hold-its-own-growing-migraine-field-allergan-execs
https://www.fiercepharma.com/marketing/can-botox-hang-cgrp-migraine-allergan-says-yes-but-analysts-are-skeptical
https://www.biopharmadive.com/news/nice-turns-down-novartis-aimovig-flagging-clinical-trial-concerns/545853/
https://endpts.com/nice-rejects-novartis-migraine-drug-aimovig-months-after-declining-to-endorse-pricey-kymriah-for-adult-use/
https://www.reuters.com/article/us-novartis-migraine/novartis-migraine-drug-not-cost-effective-uk-price-watchdog-idUSKCN1P417N?feedType=RSS&feedName=healthNews
https://www.biopharmadive.com/news/as-pharmas-revert-to-regular-price-hikes-azar-threatens-action-with-fight/545661/
https://www.biospace.com/article/top-9-really-cool-life-science-discoveries-of-the-year/
https://www.biopharmadive.com/news/amgen-launches-tv-spot-for-aimovig-in-tight-cgrp-market/539942/
https://www.fiercepharma.com/manufacturing/teva-has-buyer-for-plant-israel-could-save-200-jobs-report
https://www.fiercepharma.com/pharma/was-last-week-s-teva-sell-off-warranted-depends-who-you-ask
https://www.xconomy.com/indiana/2018/09/28/eli-lilly-migraine-drug-approved-the-third-in-new-class-of-medicines/
https://www.marketwatch.com/story/three-new-drugs-will-compete-fiercely-to-revolutionize-migraine-treatment-with-identical-6900-price-tags-2018-09-27
https://www.biopharmadive.com/news/teva-wins-much-needed-us-approval-migraine-drug-ajovy/532422/
https://www.fiercepharma.com/pharma/amgen-s-quick-aimovig-launch-has-implications-for-lilly-teva-and-alder-analyst
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004447/WC500253557.pdf
https://www.fiercepharma.com/pharma/teva-confident-september-approval-for-migraine-drug-despite-latest-celltrion-plant-citation
http://www.pharmatimes.com/news/novartis_migraine_drug_gets_ema_approval_1246290
https://pharmaphorum.com/news/breakthrough-migraine-prevention-treatment-approved-in-europe/
Market Place
Share 
